Affibody AB provides novel molecular imaging agents for visualizing HER2-expressing cancer
Affibody AB announced that Cancer Research, the official publication of American Association of Cancer Research (AACR), has published an article by Affibody and collaborators on the development and evaluation of a new targeting molecule that can be used for visualization of HER2-expressing cancers.
The authors reported on the development of a HER2-specific Affibody® molecule having an extremely high affinity (22 picomolar). The advantage of this high affinity for the oncogene product HER2 was shown in tumor targeting experiments and the utility of the drug for imaging purposes was demonstrated using gamma camera detection of HER2-expressing xenografted tumors within hours after injection.
Summarizing the results, Dr. Fredrik Nilsson, project manager and corresponding author said: "We have succeeded in engineering extremely high affinity into a small molecule. In molecular imaging, small size is the key to success, as it allows for rapid kinetics and high contrast imaging within hours after injection".
Original publication: A. Orlova et al.; "Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody® Molecule"; Cancer Research 2006, 66, 4339-4348.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
BTG signs agreement with Novacea and KuDOS for AQ4N
To-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases
Galapagos enters into discovery collaboration with Idenix for infectious disease programs
Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications - Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
AnaSpec and UW TechTransfer Sign Licensing Agreement for Protein Tyrosine Phosphatases
